Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/16837
Título
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study
Autor(es)
Fontán-Vela, Mario ISCIII | Hernando Sebastian, Victoria ISCIII | Olmedo, Carmen | Coma, Ermengol | Martínez, Montse | Moreno-Perez, David | Lorusso, Nicola | Vázquez Torres, María | Barbas del Buey, José Francisco | Roig-Sena, Javier | Pastor, Eliseo | Galmés Truyols, Antònia | Artigues Serra, Francisca | Sancho Martínez, Rosa María | Latasa Zamalloa, Pello | Pérez Martínez, Olaia | Vázquez Estepa, Ana | García Rojas, Amós José | Barreno Estévez, Ana Isabel | Sánchez-Migallón Naranjo, Alonso | Pérez Martín, Jaime Jesús | Peces Jiménez, Pilar | Morales Romero, Raquel | Castilla, Jesús | García Cenoz, Manuel | Huerta Huerta, Marta | Boone, An Lieve Dirk | Macías Ortiz, María José | Álvarez Río, Virginia | Rodríguez Recio, María Jesús | Merino Díaz, María | Berradre Sáenz, Belén | Villegas-Moreno, María Teresa ISCIII | Limia, Aurora | Diaz Franco, Asuncion ISCIII | Monge Corella, Susana ISCIII | Spanish MPOX vaccine effectiveness study group | Jarrin-Vera, Inmaculada ISCIII
Fecha de publicación
2024
Cita
Clin Infect Dis. 2024 Feb 17;78(2):476-483.
Idioma
Inglés
Tipo de documento
research article
Resumen
Background: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for individuals at high-risk of mpox, including those receiving pre-exposure prophylaxis for HIV (HIV-PrEP). Our aim was to assess the effectiveness of one dose of MVA-BN vaccine as pre-exposure against mpox virus (MPXV) infection in persons on HIV-PrEP. Methods: We conducted a national retrospective cohort study between July 12 and December 12, 2022. Individuals ≥18 years, receiving HIV-PrEP as of July 12 and with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of MVA-BN vaccine and unvaccinated controls of the same age group and region. We used a Kaplan-Meier estimator and calculate risk ratios (RR) and vaccine effectiveness (VE = 1-RR). Results: We included 5,660 matched pairs, with a median follow-up of 62 days (interquartile range 24-97). Mpox cumulative incidence was 5.6 per 1,000 (25 cases) in unvaccinated and 3.5 per 1,000 (18 cases) in vaccinated. No effect was found during days 0-6 post-vaccination (VE -38.3; 95% confidence interval (95%CI): -332.7; 46.4), but VE was 65% in ≥7 days (95%CI 22.9; 88.0) and 79% in ≥14 days (95%CI 33.3; 100.0) post-vaccination. Conclusions: One dose of MVA-BN vaccine offered protection against mpox in a most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time.
Palabras clave
Versión en línea
DOI
Aparece en las colecciones
Ficheros en el ítem
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- EffectivenessModifiedVacciniaA ...
- Tamaño:
- 514.7Kb
- Formato:
- Descripción:
- Articulo
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- Supplementary_EffectivenessMVA ...
- Tamaño:
- 823.1Kb
- Formato:
- Descripción:
- supplementary material
Ítems relacionados
Mostrando ítems relacionados por Título, autor o palabras clave.
-
2023-01
research article
Monge Corella, Susana ISCIII; Latasa Zamalloa, Pello; Sierra Moros, María José; et al.